Too, Chow WeiChow WeiTooPO-CHIN LIANGChotipanich, ChanisaChanisaChotipanichVenkatanarashima, NandaNandaVenkatanarashimaLo, Richard HgRichard HgLoZhuang, Kun DaKun DaZhuangTan, ZehaoZehaoTanGogna, ApoorvaApoorvaGognaNg, David Chee-EngDavid Chee-EngNgLoke, Kelvin Siu-HoongKelvin Siu-HoongLokeChao, YeeYeeChaoWorakitsitisatorn, AkeanongAkeanongWorakitsitisatornBoonsingma, NathapolNathapolBoonsingmaLee, Rheun-ChuanRheun-ChuanLee2025-08-292025-08-292025-08https://scholars.lib.ntu.edu.tw/handle/123456789/731723Aim: Asia-Pacific guidelines recommend selective internal radiation therapy (SIRT) as an alternative to transarterial chemoembolization for patients with intermediate or advanced hepatocellular carcinoma (HCC) and, in more limited circumstances, for metastatic colorectal cancer (mCRC). This multicenter, single-arm, prospective, observational registry evaluated safety and efficacy of SIRT with 90Y resin microspheres for HCC or mCRC in Asia. Patients & methods: Adults (n = 202) with HCC or mCRC eligible for, and scheduled to receive, SIRT with 90Y resin microspheres at participating centers were recruited. Dosimetry methods used were body surface area or partition model at the physician’s discretion. The primary endpoints were overall response rate (ORR), frequency of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), and liver function baseline changes. Results: ORR at 3 or 6 months was 56% (HCC) and 33% (mCRC). 491 TEAEs were reported in 125 patients and 71 SAEs were reported in 29 patients. Performance status was maintained or improved in most patients 6 months after SIRT. Conclusion: SIRT may offer clinicians a targeted, single-use approach for HCC or mCRC palliative care or for tumor down-sizing or down-staging in Asia. Controlled trials of SIRT using personalized dosimetry could further define a role for SIRT in these populations.enAsiaHepatocellular carcinomametastatic colorectal cancerregistriesselective internal radiation therapy[SDGs]SDG3Real-world outcomes of selective internal radiation therapy with Y resin microspheres in HCC/mCRC: RESIN registry Asia.journal article10.1080/14796694.2025.252486240662675